Treatment Patterns in Alpha-Blocker Therapy for Benign Prostatic Hyperplasia
|
|
- Linette Payne
- 6 years ago
- Views:
Transcription
1 510732JMHXXX / American Journal of Men s HealthSchoenfeld et al. research-article2013 Article Treatment Patterns in Alpha-Blocker Therapy for Benign Prostatic Hyperplasia American Journal of Men s Health 2014, Vol. 8(3) The Author(s) 2013 Reprints and permissions: sagepub.com/journalspermissions.nav DOI: / jmh.sagepub.com Michael J. Schoenfeld, MA 1, Emily F. Shortridge, PhD 1, Steven C. Gelwicks, MS 1, Zhanglin Cui, PhD 1, and David G. Wong, MD 1 Abstract This study examined treatment patterns and patient characteristics of men initiating alpha adrenergic blocker therapy (alpha-blocker) for benign prostatic hyperplasia (BPH). The 2009 Thomson Reuters MarketScan Database was used to identify the newly initiated alpha-blocker: men 40 years old with continuous medical and pharmacy coverage for 12 months before and after alpha-blocker initiation, with no alpha-blocker or 5-alpha-reductase inhibitors in the previous year, and with 1 BPH diagnosis within 1 month before and 6 months after alpha-blocker initiation. This study analyzed patient demographics, clinical characteristics, adherence (percentage of men achieving medication possession ratio [MPR] 0.8), restarting the same alpha-blocker after discontinuation, switching to another BPH medication, and type of alphablocker (alpha 1 type selective or alpha 1 subtype selective agents). T tests and chi-square tests compared differences at the.05 significance level. A total of 13,474 men met the study criteria (mean age of 63.1 years). Two thirds of the men discontinued alpha-blocker in the 12-month period, among which restarts or switches were statistically different (p =.036) but numerically similar across cohorts. Adherence for alpha 1 type selective agents versus alpha 1 subtype selective agents at 6 months was 43.3% versus 38.1% (p <.01); at 12 months, 34.4% versus 30.5% (p <.01). Alpha-blocker discontinuation rates were high, which confirms low medication adherence reported among medications for several other chronic conditions; therefore, it is necessary to understand the reasons for alpha-blocker discontinuation. Keywords alpha-blocker therapy, benign prostatic hyperplasia, medication adherence, treatment Lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH), hereafter referred to as BPH-LUTS (Wei, Calhoun, & Jacobsen, 2007), constitute bothersome chronic symptomatic conditions that are increasingly common as men age (Lepor, 2004; Roehrborn, 2008). By definition, BPH is a histological diagnosis that is made following prostate biopsy; however, BPH-LUTS is often identified and treated based solely on clinical presentation (Fourcade et al., 2012). The LUTS, suggestive of BPH, include symptoms such as urinary frequency, incomplete voiding, and nocturia. Symptoms may be measured by clinically validated instruments, such as the International Prostate Symptom Score (Barry et al., 1992) and may serve as a measure of symptom severity at baseline and a measure of efficacy following treatment. One class of therapeutic agents for the first-line treatment of mildly to moderately bothersome BPH-LUTS is generally called alpha-blockers, and the physiologic action of this class blocks the alpha 1 adrenergic type receptors of the lower urinary tract. Among the alpha 1 types, there are three subtypes: alpha 1 a/c, alpha 1 b, and alpha1 d (Schwinn & Roehrborn, 2008). Of the therapeutic agents, prazosin, doxazosin, and terazosin are alpha 1 blockers that block all three subtypes, and they are hereafter referred to as alpha 1 selective (Schwinn & Roehrborn, 2008). Tamsulosin, alfuzosin, and silodosin are considered alpha 1 subtype selective and are hereafter referred to as alpha 1 subtype selective (Table 1; Schwinn & Roehrborn, 2008). Depending on plasma concentration, alpha 1 selective agents (i.e., prazosin, doxazosin, and terazosin) may reduce arteriolar resistance and may be associated with various vascular sequelae, such as dizziness, lightheadedness, fainting, hypotension, and postural hypotension (Lepor, 2008). More recently developed alpha 1 subtype 1 Eli Lilly and Company, Indianapolis, IN, USA Corresponding Author: Michael J. Schoenfeld, Global Health Outcomes, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. schoenfeld_michael@lilly.com
2 268 American Journal of Men s Health 8(3) Table 1. Baseline Patient Characteristics for all Benign Prostatic Hyperplasia Patients. Overall (N = 13,474) Alpha 1 type selective (n = 1,731; 12.8%) Alpha 1 subtype selective (n = 11,743; 87.2%) p Value comparing alpha 1 type selective versus alpha 1 subtype selective Age, mean ± SD 63.1 ± ± ± Age group, n (%) (4.8) 82 (4.7) 567 (4.8) ,797 (20.8) 398 (23.0) 2,399 (20.4) ,669 (34.7) 632 (36.5) 4,037 (34.4) 65+ 5,359 (39.8) 619 (35.8) 4,740 (40.4) Type of alpha-blocker, n (%) Alpha 1 type selective 1,731 (12.8) N/A N/A N/A Terazosin 922 (6.8) N/A N/A Doxazosin 809 (6.0) N/A N/A Alpha 1 subtype selective 11,743 (87.2) N/A N/A Tamsulosin 9,804 (72.8) N/A N/A Alfusozin 1,545 (11.5) N/A N/A Silodosin 394 (2.9) N/A N/A Insurance plan type, n (%) <.0001 Managed care 10,255 (76.1) 1,426 (82.3) 8,829 (75.2) COMP 2,642 (19.6) 235 (13.6) 2,407 (20.5) HDDP/CDHP 268 (2.0) 29 (1.7) 239 (2.0) Unknown/missing 309 (2.3) 41 (2.4) 268 (2.3) Annual co-pay, $ mean ± SD ($ median) All co-pay $750 ± 730 ($560) $631 ± 647 ($439) $767 ± 740 ($577) <.0001 Pharmacy co-pay $531 ± 583 ($365) $411 ± 489 ($255) $548 ± 593 ($385) <.0001 Alpha-blocker co-pay $96 ± 121 ($50) $43 ± 60 ($23) $104 ± 126 ($60) <.0001 Note. BPH = benign prostatic hyperplasia; COMP = comprehensive health plan (preventative and catastrophic coverage); HDDP/CDHP = high deductible or consumer-directed health plan; N/A = not applicable; SD = standard deviation. T test was used for continuous variables and chi-square test for categorical variables. selective agents (i.e., tamsulosin, alfuzosin, and silodosin) have similar high affinity and selectivity for the alpha 1A adrenergic receptors that are located in the prostate and have a lower affinity for receptors that are located in the blood vessels. These agents have been reported to work effectively to relieve the symptoms of BPH-LUTS, with a low incidence of orthostatic and vasodilatory side effects (Lepor, 2008). There are little data measuring alpha-blocker medication adherence, and there is little information about factors that might affect patient adherence to these therapies. Medication adherence across other chronic conditions is low, regardless of the severity of the disease or whether the disease is symptomatic (Yeaw, Benner, Walt, Sian, & Smith, 2009). The evidence suggests that adherence is not a drug-specific behavior, but understanding patterns of specific drugs or conditions may provide more tailored pathways to improve patient adherence and, ultimately, to patient health. In the case of BPH-LUTS, in which symptoms often interfere with functional status, adherence may improve symptom severity and health-related quality of life (Fourcade et al., 2012; Wilson & Cleary, 1995). Given the relative scarcity of literature on adherence to alpha-blockers, this study uses a medical claims database to examine several key factors. The main objective of this study is to describe adherence patterns among men who initiate alpha-blocker therapy to treat BPH-LUTS and to evaluate treatment patterns that may influence adherence. Method Study Design, Sample Selection, and Data Source A retrospective analysis, funded and analyzed by Eli Lilly and Company, was performed by use of the 2009 Thomson Reuters MarketScan Database to identify BPH-LUTS patients who initiated alpha-blocker therapy in The date of alpha-blocker initiation was defined as the index date. Men were included in the study if they were 40 years or older at index with continuous medical and pharmacy coverage for the 12 months before and 12 months after alpha-blocker initiation (Figure 1). Men were excluded from the study if they had documented use of an alpha-blocker, 5-alpha-reductase inhibitor (5-ARI), or other BPH-LUTS therapy in the previous year, or if they had a BPH-LUTS-related procedure code 1 month before and up to 6 months after alpha-blocker initiation (Wei et al., 2007). Diagnostic and procedure codes were derived from the National Institutes of Health publication, Urologic Diseases in America, to provide a more objective definition of the disease (Wei et al., 2007).
3 Schoenfeld et al. 269 Patients in the 2009 Thompson Reuters MarketScan Database N = 22,172,407 Statistical Analyses Patients who initiated an alpha blocker in 2009 N = 509,878 (100.0%) Patients with continuous pharmaceutical and medical benefit enrollment in 1 year prior to and 1 year post alpha blocker initiation N = 281,993 (55.3%) Male patients aged 40 years at the index date. N = 255,843 (50.2%) Patients did not use alpha blocker and 5-ARIs in the prior 1 year N = 71,436 (14.0%) Patients had at least 1 BPH diagnosis based on NIH criteria a between-30 days and +180 days after the alpha blocker initiation N = 13,474 (2.6%) Figure 1. Population attrition. Note. 5-ARIs = 5-alpha-reductase inhibitors; BPH = benign prostatic hyperplasia; NIH = National Institutes of Health. a. Reported by International Classification of Diseases, Ninth Revision, diagnosis or procedure code (Wei et al., 2007). Patient demographics, alpha-blocker persistence and adherence, other patterns of alpha-blocker use, and annual medication co-pay data were summarized for all BPH-LUTS patients and by the alpha 1 type selective (i.e., prazosin, doxazosin, and terazosin) or alpha 1 subtype selective (i.e., tamsulosin, alfuzosin, and silodosin) therapy cohorts. Persistence of alpha-blocker use was defined as the length of therapy from the index date to the earliest ending date of the last prescription, which was defined as either the date of the first gap of >60 days between prescriptions or the end of the follow-up period (6 or 12 months). Adherence to alpha-blockers was measured by medication possession ratio (MPR) in the 6-month and 12-month follow-up periods. The numerator in the MPR is the total daily supply of all of the prescriptions over the period, and the denominator is the duration from the index date to the end of the period. The overall adherence rate was defined as the percentage of patients with an MPR 0.8 (i.e., prescription coverage for 80% or more of days in the follow-up period). Patterns of alphablocker use that were examined included continuing or discontinuing therapy. Of those who discontinued therapy, patterns of restarting, switching, or terminating alpha-blocker therapy were evaluated. Continuation was defined as having no gap of greater than 60 days in prescriptions over the 1-year follow-up period. Discontinuation was defined by a gap of greater than 60 days in prescriptions within the 1-year follow-up period. Restarting therapy was defined as a prescription-fill within the year of the same alpha-blocker therapy, after a gap of greater than 60 days. Switching therapy was defined as a prescription-fill of a different alpha-blocker or a new BPH-LUTS medication, such as a 5-ARI, after discontinuing the initial alpha-blocker. Terminating therapy was defined as discontinuing the initial BPH-LUTS medication without restarting it or any other BPH-LUTS medication. T tests and chi-square tests compared differences at the.05 significance level. A sensitivity analysis was performed to assess whether the addition of a 5-ARI within 1-year postindex had any effect on adherence or persistence to alpha-blocker therapy, as the safety profile of a combination of alpha-blockers and 5-ARIs may not be well tolerated by patients. Results A total of 13,474 men, with a mean age of 63 years, met inclusion criteria for the study; of these men, 87.2% used an alpha 1 subtype selective agent (i.e., tamsulosin, alfuzosin, and silodosin; Table 1). Overall, 38.8% of men were adherent at 6 months, and 31.0% of men were adherent at 12 months (Figure 2). Among the men who discontinued therapy, 10.3% restarted on the same alphablocker therapy, 8.7% switched to a different BPH-LUTS therapy, and 47.1% discontinued entirely (terminated; Figure 3). There were few differences in baseline characteristics between the alpha 1 type selective (i.e., prazosin, doxazosin, and terazosin) and alpha 1 subtype selective (i.e., tamsulosin, alfuzosin, and silodosin) cohorts; due to the large sample size, they are statistically significantly different but not considered to be meaningful (Table 1). The average annual co-pay for alpha-blocker therapy was $96 (SD = $121), which constitutes about 18% of all prescription drug co-pays. Mean co-pays for alpha 1 subtype selective (i.e., tamsulosin, alfuzosin, and silodosin) users were significantly higher ($104 ± 126 vs. $43 ± 60), and alpha-blocker co-pays constituted a greater percentage of all pharmacy co-pays among alpha 1 subtype selective (i.e., tamsulosin, alfuzosin, and silodosin) users. Men on alpha 1 subtype selective agents (i.e., tamsulosin, alfuzosin, and silodosin) were significantly less adherent at 6 and 12 months (38.1% vs. 43.3%, p <.001; 30.5% vs. 34.4%, p =.001; Figure 2). Men on alpha 1 type selective agents (i.e., prazosin, doxazosin, and terazosin) were more likely to restart or switch therapy on discontinuation. A total of 16.9% of men on alpha 1 type selective agents (i.e., prazosin, doxazosin, and terazosin) restarted and 15.1% switched therapies, compared to 15.4% and
4 270 American Journal of Men s Health 8(3) Figure 2. Alpha-blocker therapy adherence: total and cohorts. Note. ED = erectile dysfunction; n = number. Alpha-blocker therapy adherence rate was defined as the percentage of patients with 0.8 medication possession ratio. Table 2. Alpha-Blocker Therapy Pattern for Cohorts Within 1 Year. Alpha 1 type selective, n (%) Alpha 1 subtype selective, n (%) p value Figure 3. Alpha-blocker therapy pattern for all BPH patients within 1 year. Note. BPH = benign prostatic hyperplasia; N = number. a. Continued alpha-blocker medication in 1-year follow-up period; a gap of 60 days between alpha-blocker prescriptions was considered medication continuation. b. Discontinued alpha-blocker medication in 1-year follow-up period; a gap of >60 days between alpha-blocker prescriptions was considered medication discontinuation. c. Restarted the same initial alpha-blocker medication, after a gap of >60 days within 1-year follow-up period. d. Switched to a new benign prostatic hyperplasia medication (including a different alpha-blocker) within 1-year follow-up period. e. Terminated benign prostatic hyperplasia medication within 1-year follow-up period. 12.9%, respectively, of men on alpha 1 subtype selective agents (i.e., tamsulosin, alfuzosin, and silodosin; p =.036; Table 2). Men on alpha 1 type selective agents (i.e., prazosin, doxazosin, and terazosin) were also more persistent; at 6 months persistence was days for alpha 1 type selective agents (i.e., prazosin, doxazosin, and terazosin) compared to days for alpha 1 subtype selective agents (i.e., tamsulosin, alfuzosin, and silodosin; p <.001), and at 12 months, persistence was Continueda 608 (36.2) 3,889 (33.5).032 Discontinuedb 1,072 (63.8) 7,706 (66.5) Treatment pattern Restartedc 181 (10.8) 1,185 (10.2).036 Switchedd 162 (9.6) 995 (8.6) Terminatede 729 (43.4) 5,526 (47.7) a. Continued alpha-blocker medication in 1-year follow-up period; a gap of 60 days between alpha-blocker prescriptions was considered medication continuation. b. Discontinued alpha-blocker medication in 1-year follow-up period; a gap of >60 days between alpha-blocker prescriptions was considered medication discontinuation. c. Restarted the same initial alpha-blocker medication, after a gap of >60 days within 1-year follow-up period. d. Switched to a new benign prostatic hyperplasia medication (including a different alpha-blocker) within 1-year follow-up period. e. Terminated benign prostatic hyperplasia medication within 1-year follow-up period. days versus days (p =.002), respectively (data not reported). Continuation rates across time are almost identical for alpha 1 type selective (i.e., prazosin, doxazosin, and terazosin) and alpha 1 subtype selective (i.e., tamsulosin, alfuzosin, and silodosin) agents. Analyses to examine if 5-ARI use affected adherence and persistence to alpha-blocker therapy identified that adherence to and persistence with alpha-blockers remained similar after removing 5-ARI patients from the analysis (data on file).
5 Schoenfeld et al. 271 Discussion Nearly 40% of men who initiated alpha-blocker therapy continued for 6 months, and about a third of men continued for 1 year, which is similar to the adherence rates seen in other chronic diseases (Yeaw et al., 2009). Among men who discontinued, the majority did not restart or switch therapy in the course of the study. Modest differences emerged when adherence patterns by selectivity of alpha-blockers were examined. Men initiating therapy on alpha 1 subtype selective agents (i.e., tamsulosin, alfuzosin, and silodosin) were significantly less likely to continue therapy at 6 months and 1 year; they were also significantly less likely to switch or restart therapy than were men who initiated therapy on alpha 1 type selective agents (i.e., prazosin, doxazosin, and terazosin). While these findings were statistically significant, qualitatively, the average man on an alpha 1 subtype selective agent (i.e., tamsulosin, alfuzosin, and silodosin) was slightly less likely to continue, switch, or restart alpha-blocker therapy than the average man on an alpha 1 type selective agent (i.e., prazosin, doxazosin, and terazosin). The cost of therapy might be one possible explanation for the marginal differences this study observed in adherence and persistence by type of alpha-blocker therapy (Choudhry et al., 2011). In this study, men on alpha 1 subtype selective agents (i.e., tamsulosin, alfuzosin, and silodosin) faced slightly higher cost-sharing, both as an average value and as a percentage of total pharmacy costsharing. All alpha 1 type selective agents (i.e., prazosin, doxazosin, and terazosin) and some alpha 1 subtype selective agents (i.e., tamsulosin, alfuzosin, and silodosin) were generic at the time of this study, so the cost differential is not surprising. At the time of this study, most patients (87%) were taking an alpha 1 subtype selective agent (i.e., tamsulosin, alfuzosin, and silodosin), which was more expensive than the alpha 1 type selective (i.e., prazosin, doxazosin, and terazosin) alternatives. Several studies have demonstrated that the cost of therapy has a significant, but marginal, effect on adherence (Choudhry et al., 2011; Zhang et al., 2010). This study conducted subanalyses on patients who initiated 5-ARIs during the course of the study and hypothesized that these men might experience more medication-related side effects and, thus, discontinue at a higher rate; however, no difference in the subanalysis was seen. In the literature, a number of other factors, which could not be captured in our database, have been proposed as contributing to nonadherence. Some of these factors include therapy-related factors (e.g., adverse events or inconvenience), patient-related factors (e.g., the degree of bother the condition imparts), disease-related factors (e.g., symptom severity), and health-system factors (e.g., health care provider expectation setting). The literature tends to suggest that a constellation of these factors, and the medication-related and health plan-related factors that were measured in this study, contribute to patient medication-related behaviors (Kripalani, Yao, & Haynes, 2007). This study has several limitations. The quality of claims data is dependent on the accuracy of reporting and coding; however, standardized diagnostic and National Drug Codes minimize the variation in coding. Incident cases are difficult to identify, making assessments of treatment phases difficult; this study may have identified men who had already tried alpha-blocker therapy at least once. By including a lead-in period and by requiring continuous health care coverage, this challenge was minimized, but it still stands as a limitation. Information for BPH-LUTS, such as severity of disease, which may influence patient behavior or reasons for discontinuation, is not captured in claims data. Notably the claims database is not subject to recall bias, as when patients are surveyed about pharmaceutical use and treatment patterns. Results from this analysis apply only to the insured population in health plans that are comparable to those included in the database; however, the 2009 Thomson Reuters MarketScan Database contains a large, welldefined population, which has been used frequently in research studies like this one. Consistent with the broader literature about patient adherence in chronic diseases, this study finds that the majority of men discontinue alpha-blocker therapy, although about 20% subsequently resume or switch alpha-blocker therapy. The type of therapy seemed marginally important in observed treatment patterns; men on alpha 1 type selective agents (i.e., prazosin, doxazosin, and terazosin) are slightly more adherent to therapy than are men on alpha 1 subtype selective agents (i.e., tamsulosin, alfuzosin, and silodosin), and they are more likely to subsequently restart or switch therapy. Cost may play a key role in type of therapy, as men who faced smaller cost-sharing amounts adhered better to therapy than those who faced larger cost-sharing amounts. Other unmeasured dimensions, such as treatment efficacy and treatment expectations, likely also influence patient behavior in alpha-blocker use. Additional research is needed to understand how the components of cost, efficacy, medication-related side effects, patient lifestyles, and other factors work together to influence alpha-blocker use. It is important to understand reasons for alpha-blocker discontinuation because men who discontinue therapy will likely continue to experience bothersome symptoms. Acknowledgments The authors would like to thank Teri Tucker, BA, of inventiv Health Clinical, for her editorial contributions to this article, and Rebecca McCracken, MSPH, also of inventiv Health Clinical, for her writing contributions to this article.
6 272 American Journal of Men s Health 8(3) Declaration of Conflicting Interests The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was funded by Eli Lilly and Company. References Barry, M. J., Fowler, F. J., Jr., O Leary, M. P., Bruskewitz, R. C., Holtgrewe, H. L., Mebust, W. K., & Cockett, A. T. (1992). The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. Journal of Urology, 148, Choudhry, N. K., Avorn, J., Glynn, R. J., Antman, E. M., Schneeweiss, S., Toscano, M.,...Shrank, W. H. (2011). Full coverage for preventive medications after myocardial infarction. New England Journal of Medicine, 365, Fourcade, R. O., Lacoin, F., Rouprêt, M., Slama, A., Le Fur, C., Michel, E., & Cottê, F. E. (2012). Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia. World Journal of Urology, 30, Kripalani, S., Yao, X., & Haynes, R. B. (2007). Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Archives of Internal Medicine, 167, Lepor, H. (2004).Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Reviews in Urology, 6(Suppl. 9), S3-S10. Lepor, H. (2008). The evolution of alpha-blockers for the treatment of benign prostatic hyperplasia. Reviews in Urology, 8(Suppl. 4), S3-S9. Roehrborn, C. G. (2008). Pathology of benign prostatic hyperplasia. International Journal of Impotence Research, 20(Suppl. 3), S11-S18. Schwinn, D. A., & Roehrborn, C. G. (2008). Alpha1- adrenoceptor subtypes and lower urinary tract symptoms. International Journal of Urology, 15, Wei, J. T., Calhoun, E. A., & Jacobsen, S. J. (2007). Benign prostatic hyperplasia. In M. S. Litwin & C. S. Saigal (Eds.), Urologic diseases in America (NIH Publication No , pp ). Washington, DC: US Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Wilson, I. B., & Cleary, P. D. (1995). Linking clinical variables with health-related quality of life. A conceptual model of patient outcomes. Journal of the American Medical Association, 273, Yeaw, J., Benner, J. S., Walt, J. G., Sian, S., & Smith, D. B. (2009). Comparing adherence and persistence across 6 chronic medication classes. Journal of Managed Care Pharmacy, 15, Zhang, Y., Lave, J. R., Donohue, J. M., Fischer, M. A., Chernew, M. E., & Newhouse, J. P. (2010). The impact of Medicare Part D on medication adherence among older adults enrolled in Medicare-Advantage products. Medical Care, 48,
Evaluation of Recent Trends in Treatment Patterns Among Men With Benign Prostatic Hyperplasia
469245JMHXXX10.1177/1557988312469245A merican Journal of Men s HealthKruep et al. Article Evaluation of Recent Trends in Treatment Patterns Among Men With Benign Prostatic Hyperplasia American Journal
More informationLONG-TERM SAFETY AND EFFICACY OF TAMSULOSIN FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA
0022-5347/03/1702-0498/0 Vol. 170, 498 502, August 2003 THE JOURNAL OF UROLOGY Printed in U.S.A. Copyright 2003 by AMERICAN UROLOGICAL ASSOCIATION DOI: 10.1097/01.ju.0000076140.68657.fd LONG-TERM SAFETY
More informationREPORTS. Clinical and Economic Outcomes in Patients Treated for Enlarged Prostate
Clinical and Economic Outcomes in Patients Treated for Enlarged Prostate Michael James Naslund, MD, MBA; Muta M. Issa, MD, MBA; Amy L. Grogg, PharmD; Michael T. Eaddy, PharmD, PhD; and Libby Black, PharmD
More informationThe Clinical and Economic Benefit of Early Avodart Use vs Early Finasteride Use (Study: 8AVO027HO)
The Clinical and Economic Benefit of Early Avodart Use vs Early Finasteride Use (Study: 8AVO027HO) November 2011 (Revised May 2012) Prepared for: GlaxoSmithKline Please direct comments and questions to:
More informationAlpha antagonists from initial concept to routine clinical practice
european urology 50 (2006) 635 642 available at www.sciencedirect.com journal homepage: www.europeanurology.com Editorial 50th Anniversary Alpha antagonists from initial concept to routine clinical practice
More informationRESEARCH. Katrina Wilcox Hagberg, 1 Hozefa A Divan, 2 Rebecca Persson, 1 J Curtis Nickel, 3 Susan S Jick 1. open access
open access Risk of erectile dysfunction associated with use of 5-α reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink
More informationKey words: Lower Urinary Tract Symptoms (LUTS), Prostatic Hyperplasia, Alpha-1 Adrenoceptor Antagonists, Tamsulosin, Terazosin.
The Professional Medical Journal DOI: 10.17957/TPMJ/17.4102 ORIGINAL PROF-4102 PROSTATIC HYPERPLASIA; COMPARISON BETWEEN TAMSULOSIN AND TERAZOSIN FOR EFFICACY IN MEDICAL MANAGEMENT OF LOWER URINARY TRACT
More informationBenign Prostatic Hyperplasia (BPH):
Benign Prostatic Hyperplasia (BPH): Evidence Based Guidelines for Primary Care Providers Jeanne Martin, DNP, ANP-BC Objectives 1. Understand the pathophysiology and prevalence of BPH 2. Select the appropriate
More informationMedical Therapy for Benign Prostatic Hyperplasia Present and Future Impact
REPORTS Medical Therapy for Benign Prostatic Hyperplasia Present and Future Impact Muta M. Issa, MD, MBA; Timothy S. Regan, BPharm, RPh, CPh Abstract The purpose of this manuscript is to provide clinicians,
More informationCialis. Cialis (tadalafil) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.22 Subject: Cialis Page: 1 of 5 Last Review Date: September 15, 2017 Cialis Description Cialis (tadalafil)
More informationLiterature Scan: Drugs for BPH
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationThe Journal of International Medical Research 2012; 40:
The Journal of International Medical Research 2012; 40: 899 908 Comparison of α-blocker Monotherapy and α-blocker Plus 5α-Reductase Inhibitor Combination Therapy Based on Prostate Volume for Treatment
More informationIncreasing Awareness, Diagnosis, and Treatment of BPH, LUTS, and EP
Introduction to Enlarged Prostate E. David Crawford, MD Professor of Surgery (Urology) and Radiation Oncology Head, Urologic Oncology E. David Crawford Endowed Chair in Urologic Oncology University of
More informationCialis. Cialis (tadalafil) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.06.02 Subject: Cialis Page: 1 of 5 Last Review Date: September 18, 2015 Cialis Description Cialis (tadalafil)
More informationRole of silodosin in patients with LUTS/BPE non responding to medical treatment with tamsulosin: a prospective, open-label, pilot study
European Review for Medical and Pharmacological Sciences 2017; 21: 4941-4945 Role of silodosin in patients with LUTS/BPE non responding to medical treatment with tamsulosin: a prospective, open-label,
More informationThe Evolution of Combination Therapy. US men eligible for BPH treatment * with projected population changes
The Management of BPH & The Impact of Combination Therapy Results Combination of Avodart and Tamsulosin (CombAT) Medical Therapy of Prostate Symptoms (MTOPS) Dr. Jack Barkin, md, fics, facs, dabu, Mcert
More informationISSN: (Print) (Online) Journal homepage:
Archives of Andrology Journal of Reproductive Systems ISSN: 0148-5016 (Print) (Online) Journal homepage: http://www.tandfonline.com/loi/iaan19 CHANGE IN INTERNATIONAL PROSTATE SYMPTOM SCORE AFTER TRANSURETHRAL
More informationTitle of Research Thesis:
Eastern Michigan University By Fatai Osinowo Adviser s Name: Dr. Stephen Sonstein, PhD Title of Research Thesis: A sub-analyses from the Benign Prostatic Hyperplasia (BPH) Registry and Patient survey:
More informationOffice Management of Benign Prostatic Enlargement
Focus on CME at McGill University Office Management of Benign Prostatic Enlargement Symptomatic benign prostate enlargement is a common medical problem encountered in our aging society. Watchful waiting,
More informationPATIENT INFORMATION 2017 NeoTract, Inc. All rights reserved. Printed in the USA. MAC Rev A
PATIENT INFORMATION OVER 70% OF MEN IN THEIR 60s HAVE SYMPTOMS OF BPH 1 BPH affects more than 500 million men worldwide, with many men suffering from symptoms of enlarged prostate. 1 You no longer have
More informationDuring the past decade, numerous
Benign prostatic hyperplasia (BPH) is one of the most common diseases of aging men. It is estimated that by age 60 years, greater than 50% of men will have histologically documented evidence of the disease.
More informationSingle Technology Appraisal (STA) Tadalafil for the treatment of symptoms associated with benign prostatic hyperplasia
Comment 1: the draft remit Appendix D - NICE s response to consultee and commentator comments on the draft scope and provisional matrix National Institute for Health and Clinical Excellence Single Technology
More informationEvidence-based guidelines in lower urinary tract symptoms secondary to benign prostatic hyperplasia and variation in care
REVIEW C URRENT OPINION Evidence-based guidelines in lower urinary tract symptoms secondary to benign prostatic hyperplasia and variation in care Seth A. Strope Purpose of review Guidelines have been developed
More informationClinicalTrials.gov Identifier: sanofi-aventis. Sponsor/company:
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinicalTrials.gov
More informationEfficacy and safety of tamsulosin OCAS
Original Article EFFICACY AND SAFETY OF TAMSULOSIN OCAS SPEAKMAN Efficacy and safety of tamsulosin OCAS MARK SPEAKMAN Taunton and Somerset Hospital, Taunton, UK The efficacy and safety of a new tablet
More informationBenign Prostatic Hyperplasia. Management of Benign Prostatic Hyperplasia. Goals of Therapy
Benign Prostatic Hyperplasia Management of Benign Prostatic Hyperplasia Goals of Therapy Improve or abolish lower urinary tract symptoms (LUTS) Prevent or delay clinical progression of benign prostatic
More informationGSK Clinical Study Register
In February 2013, GlaxoSmithKline (GSK) announced a commitment to further clinical transparency through the public disclosure of GSK Clinical Study Reports (CSRs) on the GSK Clinical Study Register. The
More informationOriginal Article. Introduction. Methods. Abstract
Blackwell Science, LtdOxford, UKIJUInternational Journal of Urology0919-81722003 Blackwell Publishing Asia Pty LtdNovember 20031011587594Original ArticleUsefulness of a1-blockers in BPHI Ikemoto et al.
More informationOriginal Article Japanese Urological Association. International Journal of Urology (2006) 13,
Blackwell Publishing AsiaMelbourne, AustraliaIJUInternational Journal of Urology0919-81722006 Blackwell Publishing Asia Pty Ltd2006130014051409Original ArticleTamsulosin vs doxazosin in BPH D Rahardjo
More informationα-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia; 10 Years Long-Term Results
www.kjurology.org http://dx.doi.org/10.4111/kju.2012.53.4.248 Voiding Dysfunction α-blocker Monotherapy and α-blocker Plus 5-Alpha-Reductase Inhibitor Combination Treatment in Benign Prostatic Hyperplasia;
More informationLast Review Status/Date: December Summary
Section: Surgery Effective Date: January 15, 2016 Subject: Prostatic Urethral Lift Page: 1 of 9 Last Review Status/Date: December 2015 Summary Benign prostatic hyperplasia (BPH) is a common condition in
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.HNCA.01 Effective Date: 11.16.16 Last Review Date: 04.18 Line of Business: Commercial - HNCA Revision Log See Important Reminder at the end of this policy for important
More information50% of men. 90% of men PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS. Want more information? What are the symptoms?
PATIENT FACTSHEET: BPH CONDITION AND TREATMENTS What is Benign Prostatic Hyperplasia (enlarged prostate)? Benign prostatic hyperplasia (BPH) is a noncancerous enlargement of the prostate, the gland that
More informationProstate Disease. Chad Baxter, MD
Prostate Disease Chad Baxter, MD Managing BPH and LUTS Chad Baxter, MD Department of Urology cbaxter@mednet.ucla.edu 33 nd Annual UCLA Intensive Course in Geriatric Medicine & Board Review Prevalence of
More informationUroToday International Journal. Volume 1 - August 2008
UroToday International Journal www.urotodayinternationaljournal.com Volume 1 - August 2008 Complicated Cataract Surgery in Patients Receiving Alpha-Blockers for Benign Prostatic Hyperplasia Ryan K. Miyamoto*,
More informationBenign Prostatic Hypertrophy (BPH) is the most
Medical treatment of benign prostatic hypertrophy There is little doubt that medical therapy has transformed the treatment of benign prostatic hypertrophy (BPH). The medical treatment of BPH continues
More informationThe University of Mississippi School of Pharmacy
LONG TERM PERSISTENCE WITH ACEI/ARB THERAPY AFTER ACUTE MYOCARDIAL INFARCTION: AN ANALYSIS OF THE 2006-2007 MEDICARE 5% NATIONAL SAMPLE DATA Lokhandwala T. MS, Yang Y. PhD, Thumula V. MS, Bentley J.P.
More informationGuideline for the primary care management of male lower urinary tract symptoms
review Article GUIDELINES FOR LUTS M.J. SPEAKMAN et al. As my Comment in the first section of the journal suggested, the MTOPS results have offered the possibility to general practitioners of reducing
More informationGSK Medicine: Study Number: Title: Rationale: Study Period: Objectives: Indication: Study Investigators/Centers: Research Methods: Data Source
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationInternational Clinical Development Department, Yamanouchi Pharmaceutical Co., Ltd., 17 1 Hasune 3-chome, Itabashi-ku, Tokyo , Japan
192 Journal of Health Science, 47(2) 192 22 (21) Investigation of the Effects of Tamsulosin on Blood Pressure in Normotensive, Controlled Hypertensive, and Uncontrolled Hypertensive Men with Benign Prostatic
More informationSilodosin versus naftopidil for the treatment of benign prostatic hyperplasia: A multicenter randomized trial
The study protocol was approved by the ethics committee and institutional review board of Nihon University School of Medicine. Written informed consent was obtained from all patients. From December 2007
More informationTherapeutic Strategies for Managing BPH Progression
european urology supplements 5 (2006) 997 1003 available at www.sciencedirect.com journal homepage: www.europeanurology.com Therapeutic Strategies for Managing BPH Progression John M. Fitzpatrick a, *,
More informationNew Treatment Modalities for Benign Prostatic Hyperplasia. Seung-June Oh, MD Department of Urology, Seoul National University Hospital
New Treatment Modalities for Benign Prostatic Hyperplasia Seung-June Oh, MD Department of Urology, Seoul National University Hospital Options for Treating BPH Pharmacotherapy blocker Agents for BPH + OAB
More informationThe Risk of Fracture with Taking Alpha Blockers for Treating Benign Prostatic Hyperplasia
J Prev Med Public Health 2009;42(3):165-170 DOI: 103961/jpmph2009423165 The Risk of Fracture with Taking Alpha Blockers for Treating Benign Prostatic Hyperplasia Joongyub Lee 1) Nam-Kyoung Choi 13) Sun-Young
More informationEVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT
Basrah Journal Of Surgery EVALUATION OF THE EFFICACY OF TADALAFIL IN IMPROVING LOWER URINARY TRACT SYMPTOMS IN PATIENTS WITH SYMPTOMATIC BENIGN PROSTATIC ENLARGEMENT MB, ChB, FIBMS, Assistant Professor
More informationBenign Prostatic Hyperplasia. Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary
Benign Prostatic Hyperplasia Jay Lee, MD, FRCSC Clinical Associate Professor University of Calgary Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied,
More informationProfile of Silodosin. Francesco Montorsi * Article info. Abstract
EUROPEAN UROLOGY SUPPLEMENTS 9 (2010) 491 495 available at www.sciencedirect.com journal homepage: www.europeanurology.com Profile of Silodosin Francesco Montorsi * Department of Urology, University Vita-Salute
More informationChapter 4: Research and Future Directions
Chapter 4: Research and Future Directions Introduction Many of the future research needs listed in the 1994 Agency for Health Care Policy and Research (AHCPR) clinical practice guideline Benign Prostatic
More informationMEDICAL THERAPY. Endocrine Approaches. Página 1 de 5.
Página 1 de 5 MEDICAL THERAPY Part of "32 - BENIGN PROSTATIC HYPERPLASIA" Use of pharmacologically defined and a variety of so-called alternative medications to attempt to improve BPH voiding dysfunction
More informationVictoria Sharp, MD, MBA, FAAFP. Clinical Professor of Urology and Family Medicine
Victoria Sharp, MD, MBA, FAAFP Clinical Professor of Urology and Family Medicine Victoria Sharp, MD, MBA, FAAFP Market Chief Medial Officer AmeriHealth Caritas Family of Companies Office phone: (515) 330-3740
More informationAll about the Prostate
MEN S HEALTH Dr Nick Pendleton January 16 th 2018 All about the Prostate 1 What does it do? Functions of the Prostate 1. Secretes Prostatic Fluid slightly alkaline fluid, 30% of volume of seminal fluid,
More informationUse of a-blockers and the risk of hip/femur fractures
Journal of Internal Medicine 2003; 254: 548 554 Use of a-blockers and the risk of hip/femur fractures P. C. SOUVEREIN 1,T.P.VANSTAA 1,2,A.C.G.EGBERTS 1,J.J.M.C.H.DELAROSETTE 3, C. COOPER 2 & H. G. M. LEUFKENS
More informationIntroduction. Original Article: Clinical Investigation
International Journal of Urology (2015) 22, 582--587 doi: 10.1111/iju.12741 Original Article: Clinical Investigation Treatment satisfaction and clinically meaningful symptom improvement in men with lower
More informationIJBCP International Journal of Basic & Clinical Pharmacology
Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20160772 Research Article Efficacy and safety of
More informationOriginal Article INTRODUCTION. Abstract
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2017/02 Comparison of Silodosin with Tamsulosin in Patients with Symptomatic Benign Prostatic Hyperplasia: A Prospective,
More informationEfficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study
Efficacy of Silodosin for Relieving Benign Prostatic Obstruction: Prospective Pressure Flow Study Yoshihisa Matsukawa,* Momokazu Gotoh, Tomonori Komatsu, Yasuhito Funahashi, Naoto Sassa and Ryohei Hattori
More informationThe treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 80 years
British Journal of Urology (1997), 8, 875 879 The treatment of benign prostatic hyperplasia with alpha blockers in men over the age of 8 years S.A. KAPLAN, A.E. TE, E. IKEGUCHI and R.P. SANTAROSA Department
More informationDrugTreatment of Benign Prostatic Hyperplasia and Hospital Admission for BPH-Related Surgery
European Urology European Urology 43 (2003) 528 534 DrugTreatment of Benign Prostatic Hyperplasia and Hospital Admission for BPH-Related Surgery P.C. Souverein a,*, J.A. Erkens b, J.J.M.C.H. de la Rosette
More informationRecommended drug treatment of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol
Drug review BPH Recommended drug treatment of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol Skyline Imaging Ltd The development of safe and effective drugs
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Prostatic Urethral Lift Page 1 of 19 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Prostatic Urethral Lift Professional Institutional Original Effective Date:
More informationMedical Coverage Policy Prostatic Urethral Lifts
Medical Coverage Policy Prostatic Urethral Lifts EFFECTIVE DATE:12 01 2018 POLICY LAST UPDATED: 10 03 2017 OVERVIEW Benign prostatic hyperplasia is a common condition in older men that can lead to increased
More informationMedical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily
REVIEW Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily Claus G Roehrborn 1 Raymond C Rosen 2 1 Department of Urology, University of Texas Southwestern
More informationThe Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page
The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (6), Page 1377-1386 Evaluation of Silodosin in Comparison to Tamuslosin in Treatment of Benign Prostatic Hyperplasia with lower Urinary
More informationWill Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men?
Urol Sci 2011;22(1):14 18 MINI REVIEW Will Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men? Thomas I.S. Hwang 1,2,3 * 1 Shin Kong WHS Hospital, Taipei,
More informationHyoung Woo Kim, Dae Geun Moon, Hyun Min Kim, Jong Ho Hwang, Soon Chan Kim, Sam Geuk Nam, Jun Tag Park
www.kjurology.org http://dx.doi.org/10.4111/kju.2011.52.10.681 Voiding Dysfunction Effect of Shifting from Combination Therapy to Monotherapy of α-blockers or 5α-Reductase Inhibitors on Prostate Volume
More informationShould flomax be taken at bedtime
Should flomax be taken at bedtime Adults with radiopaque lower ureteral stones of 10 mm or smaller have received tamsulosin 0.4 mg PO at bedtime for 28 days or until definite stone passage (i.e. Prostate
More informationNational Institute for Health and Care Excellence. Lower Urinary Tract Symptoms Update Addendum Consultation Table 3 rd February 5 pm 3 rd March 2015
British Association of Urological Surgeons British Association of Urological Surgeons National Institute for Health and Care Excellence Lower Urinary Tract Symptoms Update Addendum Consultation Table 3
More information1.1. Tamsulosin and depressive reactions
1.1. and depressive reactions Introduction (Omnic ) is an adrenergic alpha1-receptor (alpha1-ar) blocker. It is registered for the treatment of lower urinary tract symptoms (LUTS) related to benign prostatic
More informationIJBCP International Journal of Basic & Clinical Pharmacology
Print ISSN: 2319-2003 Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20172721 Original Research Article Patient-reported
More informationMODULE 3: BENIGN PROSTATIC HYPERTROPHY
MODULE 3: BENIGN PROSTATIC HYPERTROPHY KEYWORDS: Prostatic hypertrophy, prostatic hyperplasia, PSA, voiding dysfunction, lower urinary tract symptoms (LUTS) At the end of this clerkship, the medical student
More informationProstate Health PHARMACIST VIEW
Prostate Health PHARMACIST VIEW Prostate Definition Prostate is a gland made of fibromuscular tissue. It is about 4 cm and surrounds the neck of the bladder and the urethra. It produces seminal fluid.
More informationEvaluation of Sexual Dysfunction in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Patients
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2018/10 Evaluation of Sexual Dysfunction in Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Patients N. Narayanamoorthy,
More informationOriginal Article - Voiding Dysfunction
www.kjurology.org http://dx.doi.org/10.4111/kju.2014.55.5.335 Original Article - Voiding Dysfunction http://crossmark.crossref.org/dialog/?doi=10.4111/kju.2014.55.5.335&domain=pdf&date_stamp=2014-05-16
More informationProstatic Urethral Lift
Protocol Prostatic Urethral Lift (701151) Medical Benefit Effective Date: 04/01/18 Next Review Date: 01/19 Preauthorization No Review Dates: 05/17, 01/18 Preauthorization is not required. The following
More informationJMSCR Vol 05 Issue 07 Page July 2017
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i7.47 Original Research Article Tadalafil therapy
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Centre for Clinical Practice Surveillance Programme Clinical guideline CG97: The management of lower urinary tract symptoms in men Publication date May
More informationOVER 70% OF MEN IN THEIR 60s HAVE SYMPTOMS OF BPH 1
PATIENT INFORMATION BPH affects more than 500 million men worldwide, with many men suffering from symptoms of enlarged prostate. 1 You no longer have to be one of them! OVER 70% OF MEN IN THEIR 60s HAVE
More informationBenign Prostatic Hyperplasia and Enlarged Prostate Guidelines: How They Can Be Useful to Primary Care
Volume 1, Number 1 Weill Medical College of Cornell University Reports on Men s Urologic Health 1 Editor: Steven A. Kaplan, MD, Professor of Urology, and Chief, Institute for Bladder and Prostate Health,
More informationa 1 -adrenoceptor antagonist on uro owmetric parameters in patients with benign prostatic hyperplasia
Single dose methodology to assess the in uence of an a 1 -adrenoceptor antagonist on uro owmetric parameters in patients with benign prostatic hyperplasia S. P. Curtis, 1 I. Eardley, 2 M. Boyce, 3 P. Larson,
More informationMedical management of Benign Prostate Hyperplasia: New insights
INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN BIOLOGY AND MEDICINE ISSN: 2455-944X www.darshanpublishers.com DOI:10.22192/ijcrbm Volume 2, Issue 5-2017 Original Research Article Medical management of Benign
More informationBenign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia (BPH) Definition Prostate gland enlargement is a common condition as men get older. Also called benign prostatic hyperplasia (BPH), prostate gland enlargement can cause bothersome
More informationRelated Policies None
Medical Policy MP 7.01.151 BCBSA Ref. Policy: 7.01.151 Last Review: 12/27/2017 Effective Date: 03/01/2018 Section: Surgery End Date: 08/19/2018 Related Policies None DISCLAIMER Our medical policies are
More informationCorrespondence should be addressed to Yoshinori Tanaka;
Hindawi Advances in Urology Volume 2017, Article ID 4842025, 6 pages https://doi.org/10.1155/2017/4842025 Clinical Study The Persistence of Silodosin Monotherapy and the Reasons for Withdrawal from Treatment
More informationChapter 2: Methodology
Chapter 2: Methodology TABLE OF CONTENTS Introduction... 2 Study Selection and Data Abstraction... 2 Data Synthesis... 8 Guideline Development and Approvals... 9 Conflict of Interest... 10 Copyright 2010
More informationH6D-MC-LVHR Clinical Study Report Synopsis Page LVHR Synopsis (LY450190)
H6D-MC-LVHR Clinical Study Report Synopsis Page 1 2. LVHR Synopsis H6D-MC-LVHR Clinical Study Report Synopsis Page 2 Clinical Study Report Synopsis: Study H6D-MC-LVHR Title of Study: A Randomized, Double-Blind,
More informationEjaculation. Emission. Ejection. Orgasm
Ejaculation Emission Ejection Orgasm Ejaculation sc T10-L2 S2-4 Emission: vas deferens, prostate, bladder neck Post. Urethra distention Ejection: Pelvic Floor / bulbocavernous muscle contraction Orgasm:
More informationThe Journal of International Medical Research 2005; 33:
The Journal of International Medical Research 2005; 33: 562 573 A Comparative Study on the Safety and Efficacy of Tamsulosin and Alfuzosin in the Management of Symptomatic Benign Prostatic Hyperplasia:
More informationMonth/Year of Review: May 2014 Date of Last Review: November 2012 Source Document: OSU College of Pharmacy
Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Copyright 2012 Oregon State University. All Rights
More informationRELATIONSHIPS BETWEEN AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX, PROSTATE VOLUME, PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
American Urological Association symptom index for BPH RELATIONSHIPS BETWEEN AMERICAN UROLOGICAL ASSOCIATION SYMPTOM INDEX, PROSTATE VOLUME, AND DISEASE-SPECIFIC QUALITY OF LIFE QUESTION IN PATIENTS WITH
More informationCost-Motivated Treatment Changes in Commercial Claims:
Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non- Medical Switching August 2017 THE MORAN COMPANY 1 Cost-Motivated Treatment Changes in Commercial Claims: Implications for Non-Medical
More informationCurrent drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol
Drug review BPH Current drug management of BPH in primary care Claire Taylor MRCS, Charlotte Foley MRCS and Roger Kirby MA, MD, FRCS Urol Skyline Imaging Ltd The range of drug treatments for BPH, alone
More informationClass Update: Benign Prostatic Hyperplasia (BPH)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationREVIEW Validated questionnaires for assessing sexual dysfunction and BPH/LUTS: solidifying the common pathophysiologic link
(2008) 20, S27 S32 & 2008 Nature Publishing Group All rights reserved 0955-9930/08 $30.00 www.nature.com/ijir REVIEW Validated questionnaires for assessing sexual dysfunction and BPH/LUTS: solidifying
More informationBenign Prostatic Hyperplasia (BPH) Important Papers / Landmark. Vijayan Manogran
Benign Prostatic Hyperplasia (BPH) Important Papers / Landmark Studies Vijayan Manogran MTOPS & CombAT PLESS SMART ALTESS ALF-ONE VA PREDICT EPICS Landmark Studies MTOPS Medical Therapy of Prostatic Symptoms
More informationInvestigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia
Sakata and Morita BMC Urology 2012, 12:29 RESEARCH ARTICLE Open Access Investigation of ejaculatory disorder by silodosin in the treatment of prostatic hyperplasia Koichi Sakata 1* and Tatsuo Morita 2
More informationCIALIS (See-AL-iss) (tadalafil) tablets
1 Patient Information CIALIS (See-AL-iss) (tadalafil) tablets Read this important information before you start taking CIALIS and each time you get a refill. There may be new information. You may also find
More informationAriana L. Smith and Alan J. Wein Division of Urology, Hospital of University of Pennsylvania, Philadelphia, PA, USA
; 2011 Mini Reviews PHARMACOLOGICAL MANAGEMENT OF NOCTURIA SMITH and WEIN BJUI Outcomes of pharmacological management of with non-antidiuretic agents: does statistically significant equal clinically significant?
More informationj 727
Efficacy and Safety of the Coadministration of Tadalafil Once Daily with Finasteride for 6 Months in Men with Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia
More information